HIGHLIGHTS
- who: Xiaomi Li from the Department of Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China have published the article: Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure, in the Journal: (JOURNAL)
- what: The aim of this study was to investigate the efficacy and safety of inhibitors (TKIs) combined with immune checkpoint inhibitors (ICIs) as second-line treatment. The authors investigated possible second-line options in patients with HCC who were intolerant and progressed to SOR. This study showed that TKI combined with ICI prolonged PFS by nearly 5 months . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.